You just read:

Even with Aubagio's Recent Launch, the Impact of Gilenya and Tysabri Label Revisions Continue to Dominate Changes in the U.S. Multiple Sclerosis Market, According to a Recent BioTrends Report

News provided by

BioTrends Research Group

Jan 16, 2013, 08:00 EST